Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

Movement Disorders

Volumn 26, Issue 4, 2011, Pages 614-620

  Gallagher, Catherine L ^a,b   Oakes, Terrence R ^c   Johnson, Sterling C ^a,b   Chung, Moo K ^b,c   Holden, James E ^b   Bendlin, Barbara B ^a,b   Mclaren, Donald G ^b,d   Xu, Guofan ^a,b   Nickles, Robert J ^d   Pyzalski, Robert ^d   Dejesus, Onofre ^d   Brown, W Douglas ^e  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Aging; Disease progression; Fluorodopa positron emission tomography; Gender; Parkinson's disease

Indexed keywords

6 FLUORODOPA F 18; CARBIDOPA PLUS LEVODOPA; LEVODOPA; PRAMIPEXOLE; SELEGILINE;

ADULT; AGE; AGED; ARTICLE; BRAIN SCINTISCANNING; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE DURATION; FEMALE; GENDER; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

ADULT; AGED; BRAIN MAPPING; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE AGENTS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79955027931     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23503     Document Type: Article

References (32)

1. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
2. Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatr 2005; 76: 1217-1221.
3. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996; 119 ( Part 6): 2097-2103.
4. Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984; 11( 1 Suppl): 174-179.
5. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
6. Rinne OJ, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 2001; 40: 193-200.
7. Kaasinen V, Nurmi E, Bruck A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 2001; 124 ( Part 6): 1125-1130.
8. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989; 26: 766-770.
9. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-455.
10. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatr 1998; 64: 314-319.
11. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005; 62: 378-382.
12. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001; 16: 608-615.
13. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119 ( Part 2): 585-591.
14. Bhatt MH, Snow BJ, Martin WR, Pate BD, Ruth TJ, Calne DB. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 1991; 29: 673-677.
15. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatr 1988; 51: 745-752.
16. Brown WD, Taylor MD, Roberts AD, et al. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 1999; 53: 1212-1218.
17. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
18. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
19. Ilgin N, Zubieta J, Reich SG, Dannals RF, Ravert HT, Frost JJ. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology 1999; 52: 1221-1226.
20. SPSS, Inc. 16 ed. Chicago, 2007.
21. Nurmi E, Bergman J, Eskola O, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 2003; 48: 109-115.
22. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci; 30: 1049-1056.
23. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006; 21: 958-963.
24. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatr 2007; 78: 819-824.
25. Alves G, Muller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: the Norwegian Park West study. J Neurol Neurosurg Psychiatr 2009; 80: 851-857.
26. Borghammer P, Kumakura Y, Cumming P. Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease. Arch Neurol 2005; 62: 1480; author reply 1480-1481.
27. Sossi V, de La Fuente-Fernandez R, Holden JE, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 2002; 22: 232-239.
28. Sossi V, de la Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004; 24: 869-876.
29. Kumakura Y, Danielsen EH, Reilhac A, Gjedde A, Cumming P. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease. Acta Neurol Scand 2004; 110: 188-195.
30. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
31. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72: 705-711.
32. Grunder G. "Absolute" or "relative": choosing the right outcome measure in neuroimaging. Neuroimage 2009; 45: 258-259.